Follow
Kiran Avancha, PhD
Kiran Avancha, PhD
HonorHealth Research Institute
Verified email at honorhealth.com
Title
Cited by
Cited by
Year
Treating breast cancer in the 21st century: emerging biological therapies
G Tinoco, S Warsch, S Glück, K Avancha, AJ Montero
Journal of Cancer 4 (2), 117, 2013
1912013
A cost-benefit analysis of bevacizumab in combination with paclitaxel in the first-line treatment of patients with metastatic breast cancer
AJ Montero, K Avancha, S Glück, G Lopes
Breast cancer research and treatment 132 (2), 747-751, 2012
662012
A cost effectiveness study of eribulin versus standard single-agent cytotoxic chemotherapy for women with previously treated metastatic breast cancer
G Lopes, S Glück, K Avancha, AJ Montero
Breast cancer research and treatment 137 (1), 187-193, 2013
292013
Cost-effectiveness analysis of everolimus plus exemestane versus exemestane alone for treatment of hormone receptor positive metastatic breast cancer
V Diaby, G Adunlin, SB Zeichner, K Avancha, G Lopes, S Gluck, ...
Breast cancer research and treatment 147 (2), 433-441, 2014
202014
O. 03: cost effectiveness of immune checkpoint inhibitors in non-small cell lung cancer relative to PD-L1 expression
P Aguiar, R De Mello, H Tadokoro, I Santoro, H Babiker, K Avancha, ...
Journal of Thoracic Oncology 11 (10), S169-S170, 2016
72016
Treating breast cancer in the 21st century: emerging biological therapies. J Cancer 2013; 4 (2): 117-32
G Tinoco, S Warsch, S Glück, K Avancha, AJ Montero
5
Cost-effectiveness evaluation of abiraterone in the treatment of patients with castration-resistant prostate cancer who previously received docetaxel.
A Chopra, S Gluck, AJ Montero, KKVR Avancha, G Lopes
Journal of Clinical Oncology 30 (15_suppl), e15107-e15107, 2012
42012
Personalized management of breast cancer
TL Holloway, I Jatoi
Future Medicine Ltd., 2014
32014
Cost-effectiveness of everolimus plus exemestane in post-menopausal hormone receptor positive metastatic breast cancer.
SB Zeichner, KKVR Avancha, G Lopes, S Gluck, AJ Montero
Journal of Clinical Oncology 31 (15_suppl), 6548-6548, 2013
32013
Cost-effectiveness analysis of eribulin (E) versus treatment of physician’s choice (TPC) in patients (pts) with pretreated metastatic breast cancer (MBC).
AJ Montero, KKVR Avancha, S Gluck, GL Lopes
Journal of Clinical Oncology 30 (15_suppl), e16525-e16525, 2012
32012
COST-EFFECTIVENESS ANALYSIS OF METASTATIC BREAST CANCER TREATMENTS: A STUDY BASED ON THE BOLERO-2 TRIAL
V Diaby
The 36th Annual Meeting of the Society for Medical Decision Making, 2014
2014
EGF receptor inhibitors: Patient selection and clinical outcomes
S Warsch, G Tinoco, S Glück, K Avancha, AJ Montero
Personalized Management of Breast Cancer, 69-78, 2014
2014
Design and synthesis of core structural intermediates for novel HIV-1 protease inhibitors & synthesis, biological activity and molecular modeling of novel 20S proteasome inhibitors
KKVR Avancha
2006
POSTER SECTION C
VP MIMETICS
Bioorg. Med. Chem 13, 501, 2005
2005
Travis L Holloway
I Jatoi
The system can't perform the operation now. Try again later.
Articles 1–15